Celentano D D, Beyrer C, Natpratan C, Eiumtrakul S, Sussman L, Renzullo P O, Khamboonruang C, Nelson K E
School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA.
AIDS. 1995 Sep;9(9):1079-83. doi: 10.1097/00002030-199509000-00015.
To determine the anticipated participation in a prophylactic AIDS vaccine trial and to identify perceived benefits and barriers to enrollment of HIV-seronegative volunteers at risk of HIV infection in northern Thailand.
A cross-sectional survey.
Subjects interviewed in a cross-sectional survey included female commercial sex workers (n = 215), men attending sexually transmitted disease clinics (n = 219), conscripts in the Royal Thai Army (n = 1453), and men discharged from the army (n = 293) who had returned to civilian life. We determined AIDS vaccine knowledge and attitudes, perceived vulnerability to HIV infection, barriers and incentives to participate in a future vaccine trial and agreement to participate in a randomized trial.
Awareness of vaccines (88-97%) and AIDS vaccine development efforts (62-77%) were common and viewed to be a complement to behavior change (74-94%). Approximately 25% of subjects would definitely join a trial if asked, and an additional 38% would accept an AIDS vaccine if they were convinced it would be safe and effective. Important barriers to participation included concerns with discrimination (16-45%), short- (37-60%) and long-term (30-55%) vaccine side-effects, fear of disability and death (36-58%), and beliefs that partners would refuse to have sex (24-49%) after immunization. The principal inducement to join a trial was health insurance (62%).
Potential HIV vaccine trial participants have several fears of joining a vaccine study at this time. Information derived from Phase I/II trials is needed to address these concerns if enrollment in efficacy trials is to be successful in the near future.
确定在泰国北部预计参与预防性艾滋病疫苗试验的情况，并找出在有感染艾滋病毒风险的艾滋病毒血清阴性志愿者中，他们所认为的参与试验的益处和障碍。
横断面调查。
横断面调查中接受访谈的受试者包括女性商业性工作者（n = 215）、到性传播疾病诊所就诊的男性（n = 219）、泰国皇家军队应征入伍者（n = 1453）以及退伍后回归平民生活的男性（n = 293）。我们确定了艾滋病疫苗知识和态度、对感染艾滋病毒的易感性认知、参与未来疫苗试验的障碍和动机以及参与随机试验的意愿。
对疫苗（88 - 97%）和艾滋病疫苗研发工作（62 - 77%）的知晓情况很普遍，且被视为行为改变的一种补充（74 - 94%）。约25%的受试者如果被邀请肯定会参加试验，另外38%的受试者如果确信艾滋病疫苗安全有效就会接受。参与试验的重要障碍包括担心受到歧视（16 - 45%）、短期（37 - 60%）和长期（30 - 55%）疫苗副作用、害怕残疾和死亡（36 - 58%）以及认为接种疫苗后性伴侣会拒绝发生性行为（24 - 49%）。参与试验的主要诱因是医疗保险（62%）。
目前潜在的艾滋病毒疫苗试验参与者对参加疫苗研究存在诸多担忧。如果近期要成功开展疗效试验，就需要从I/II期试验中获取信息来解决这些担忧。
